Gritstone Bio Inc's Customers Performance

Name: Gritstone Bio Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

GRTS

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


GRTS's Source of Revenues		During the corresponding time, Gritstone Bio Inc saw a revenue deteriorated by -52.89 % year on year, sequentially revenue fell by -47.13 %. While revenue at the Gritstone Bio Inc 's corporate clients • List of GRTS Customers

for the same period Gritstone Bio Inc revnue deteriorated by -52.89 % year on year, sequentially revenue fell by -47.13 %.

• List of GRTS Customers

Gritstone Bio Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Gritstone Bio Inc's Comment on Sales, Marketing and Customers

News about Gritstone Bio Inc Contracts

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontli...

Breaking Ground: Promising Phase 2 Data for Gritstone bio s GRANITE Immunotherapy in Colorectal CancerIn a significant stride towards advancing cancer immunotherapy, Gritstone bio has announced promising interim data from its Phase 2 trial of GRANITE, an individualized neoantigen-targeting immunotherapy designed for frontline treatment in patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The initial results reveal encouraging progression-free survival (PFS), particularly in subgroups defined by circulating tumor DNA (ctDNA) metrics, although further follow-up is essential to corroborate these early findings. Promising Progression-Free Survival The interim data provide a foundation ...

Gritstone bio’s Self-Amplifying mRNA (samRNA) Vaccine Demonstrates Long-lasting Immune Response Against COVID-19 Variants

The ongoing battle against the COVID-19 pandemic has emphasized the crucial role of effective vaccines in controlling the spread of the virus. With new variants emerging, it is imperative to develop vaccines that provide durable immunity and broad utility. Gritstone bio, a pioneering biotechnology company, presented promising data on the durability and potential broad utility of its self-amplifying mRNA (samRNA) COVID-19 vaccine at the ESCMID Global 2024 conference. Their findings reveal prolonged IgG levels, neutralizing antibodies against variants of concern, and increased antigen-specific T cell responses, including among individuals living with HIV.Durable Immune ResponseGritstone bio s samRNA COVID-19 v...

GRTS's Stock Performance relative to it's Customers

GRTS's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Gritstone Bio Inc	4.61	14.61	-201.00	98
SUBTOTAL	0.00	0.00	0.00	-

Sources: Gritstone Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Gritstone Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Gritstone Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.